


COPY OF PAPERS
ORIGINALLY FILED



UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

Bayer 10203-LB3

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/424,686	11/29/1999	GUSTAV HAGEN	BAYER10.203	8382

7590 03/13/2002
NORRIS MCLAUGHLIN & MARCUS
220 East 42nd Street
30th floor
New York, NY 10017

Sequence 4-13-02

EXAMINER

WALICKA, MALGORZATA A

ART UNIT PAPER NUMBER

1652

DATE MAILED: 03/13/2002

14

Please find below and/or attached an Office communication concerning this application or proceeding.

RECEIVED
APR 25 2002
TECH CENTER 1600/2900



Application/Control Number: 09/424,686
Art Unit: 1652

Page 2

**Lack of compliance of nucleotide sequence disclosure
with 37 C.F.R. 1.821-1.825**

Examiner acknowledges transmittal of computer readable form (CFR) and paper listing of sequences on Jan. 29, 2002.

However, this application still fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth in the attached Raw Sequence Listing Error Report and Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.


Applicant is given ONE MONTH from the mailing date of this communication within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Malgorzata A. Walicka, Ph.D., whose telephone number is (703) 305-7270. The examiner can normally be reached Monday-Friday from 10:00 a.m. to 4:30 p.m.

If attempts to reach examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy, Ph.D. can be reached on (703) 308-3804. The fax phone number for this Group is (703) 305-3014.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionists whose telephone number is (703) 308-0196.

Malgorzata A. Walicka, Ph.D.
Art Unit 1652
Patent Examiner


NASHAAT T. NASHED PHD.
PRIMARY EXAMINER



Application/Control Number: 09/424,686

Art Unit: 1652

Page 3

Application No.: 09/424, 686

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a Sequence Listing as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the Sequence Listing in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the Sequence Listing in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up Raw Sequence Listing.
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the Sequence Listing is not the same as the computer readable form of the Sequence Listing as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the Sequence Listing.
- ☒ An initial or substitute paper copy of the Sequence Listing, as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212


For Patent software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

COPY OF PAPERS
ORIGINALLY FILED



BIO TECHNOLOGY
SYSTEMS
BRANCH



#13
3/1/02

APR 25 2002

RECEIVED

RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/424,686
Source: 1652
Date Processed by STIC: 2/14/2002

RECEIVED
FEB 27 2002
TECH CENTER 1600/2900

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER
VERSION 3.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND
TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:


1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
Or
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002

COPY OF PAPERS
ORIGINALLY FILED



RECEIVED
FEB 27 2002
TECH CENTER 1600/2900



1652

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/424,686

DATE: 02/14/2002
TIME: 15:18:45

Input Set : A:\pto.vsk.txt

Output Set: N:\CRF3\02142002\I424686.raw **Does Not Comply
Corrected Diskette Needed**

4 <110> APPLICANT: Hagen, Gustav
5 Siegmund, Hans-Ulrich
6 Weichel, Walter
7 Wick, Maresa
8 Zubov, Dmitry
10 <120> TITLE OF INVENTION: Human Catalytic Telomerase Sub-Unit and its Diagnostic and
Therapeutic
11 Use
13 <130> FILE REFERENCE: Bayer 10,203
15 <140> CURRENT APPLICATION NUMBER: US 09/424,686
17 <141> CURRENT FILING DATE: 1999-11-29
19 <150> PRIOR APPLICATION NUMBER: PCT/EP98/03468
21 <151> PRIOR FILING DATE: 1998-06-09
23 <160> NUMBER OF SEQ ID NOS: 7
25 <170> SOFTWARE: Microsoft Word

ERRORED SEQUENCES

171 <210> SEQ ID NO: 2
172 <211> LENGTH: 1132
E--> 173 <212> TYPE: amino acid
174 <213> ORGANISM: Homo sapiens
176 <400> SEQUENCE: 2
177 Met Pro Arg Ala Pro Arg Cys Arg Ala Val Arg Ser Leu Leu Arg Ser
178 1 5 10 15
180 His Tyr Arg Glu Val Leu Pro Leu Ala Thr Phe Val Arg Arg Leu Gly
181 20 25 30
183 Pro Gln Gly Trp Arg Leu Val Gln Arg Gly Asp Pro Ala Ala Phe Arg
184 35 40 45
186 Ala Leu Val Ala Gln Cys Leu Val Cys Val Pro Trp Asp Ala Arg Pro
187 50 55 60
189 Pro Pro Ala Ala Pro Ser Phe Arg Gln Val Ser Cys Leu Lys Glu Leu
190 65 70 75 80
192 Val Ala Arg Val Leu Gln Arg Leu Cys Glu Arg Gly Ala Lys Asn Val
193 85 90 95
195 Leu Ala Phe Gly Phe Ala Leu Leu Asp Gly Ala Arg Gly Gly Pro Pro
196 100 105 110
198 Glu Ala Phe Thr Thr Ser Val Arg Ser Tyr Leu Pro Asn Thr Val Thr
199 115 120 125
201 Asp Ala Leu Arg Gly Ser Gly Ala Trp Gly Leu Leu Leu Arg Arg Val
202 130 135 140
204 Gly Asp Asp Val Leu Val His Leu Leu Ala Arg Cys Ala Leu Phe Val
205 145 150 155 160

*invalid response must be
PRT for proteins.*

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/424,686

DATE: 02/14/2002

TIME: 15:18:45

Input Set : A:\pto.vsk.txt

Output Set: N:\CRF3\02142002\I424686.raw

207	Leu	Val	Ala	Pro	Ser	Cys	Ala	Tyr	Gln	Val	Cys	Gly	Pro	Pro	Leu	Tyr
208					165					170					175	
210	Gln	Leu	Gly	Ala	Ala	Thr	Gln	Ala	Arg	Pro	Pro	Pro	His	Ala	Ser	Gly
211				180					185					190		
213	Pro	Arg	Arg	Arg	Leu	Gly	Cys	Glu	Arg	Ala	Trp	Asn	His	Ser	Val	Arg
214				195				200					205			
216	Glu	Ala	Gly	Val	Pro	Leu	Gly	Leu	Pro	Ala	Pro	Gly	Ala	Arg	Arg	Arg
217		210					215					220				
219	Gly	Gly	Ser	Ala	Ser	Arg	Ser	Leu	Pro	Leu	Pro	Lys	Arg	Pro	Arg	Arg
220	225					230					235					240
222	Gly	Ala	Ala	Pro	Glu	Pro	Glu	Arg	Thr	Pro	Val	Gly	Gln	Gly	Ser	Trp
223					245					250					255	
225	Ala	His	Pro	Gly	Arg	Thr	Arg	Gly	Pro	Ser	Asp	Arg	Gly	Phe	Cys	Val
226				260					265						270	
228	Val	Ser	Pro	Ala	Arg	Pro	Ala	Glu	Glu	Ala	Thr	Ser	Leu	Glu	Gly	Ala
229			275					280						285		
231	Leu	Ser	Gly	Thr	Arg	His	Ser	His	Pro	Ser	Val	Gly	Arg	Gln	His	His
232		290					295					300				
234	Ala	Gly	Pro	Pro	Ser	Thr	Ser	Arg	Pro	Pro	Arg	Pro	Trp	Asp	Thr	Pro
235	305					310					315					320
237	Cys	Pro	Pro	Val	Tyr	Ala	Glu	Thr	Lys	His	Phe	Leu	Tyr	Ser	Ser	Gly
238					325					330						335
240	Asp	Lys	Glu	Gln	Leu	Arg	Pro	Ser	Phe	Leu	Leu	Ser	Ser	Leu	Arg	Pro
241			340						345					350		
243	Ser	Leu	Thr	Gly	Ala	Arg	Arg	Leu	Val	Glu	Thr	Ile	Phe	Leu	Gly	Ser
244			355					360					365			
246	Arg	Pro	Trp	Met	Pro	Gly	Thr	Pro	Arg	Arg	Leu	Pro	Arg	Leu	Pro	Gln
247		370					375					380				
249	Arg	Tyr	Trp	Gln	Met	Arg	Pro	Leu	Phe	Leu	Glu	Leu	Leu	Gly	Asn	His
250	385					390					395					400
252	Ala	Gln	Cys	Pro	Tyr	Gly	Val	Leu	Leu	Lys	Thr	His	Cys	Pro	Leu	Arg
253				405						410					415	
255	Ala	Ala	Val	Thr	Pro	Ala	Ala	Gly	Val	Cys	Ala	Arg	Glu	Lys	Pro	Gln
256				420					425					430		
258	Gly	Ser	Val	Ala	Ala	Pro	Glu	Glu	Glu	Asp	Thr	Asp	Pro	Arg	Arg	Leu
259			435					440					445			
261	Val	Gln	Leu	Leu	Arg	Gln	His	Ser	Ser	Pro	Trp	Gln	Val	Tyr	Gly	Phe
262		450					455					460				
264	Val	Arg	Ala	Cys	Leu	Arg	Arg	Leu	Val	Pro	Pro	Gly	Leu	Trp	Gly	Ser
265	465					470					475					480
267	Arg	His	Asn	Glu	Arg	Arg	Phe	Leu	Arg	Asn	Thr	Lys	Lys	Phe	Ile	Ser
268					485					490					495	
270	Leu	Gly	Lys	His	Ala	Lys	Leu	Ser	Leu	Gln	Glu	Leu	Thr	Trp	Lys	Met
271				500					505					510		
273	Ser	Val	Arg	Asp	Cys	Ala	Trp	Leu	Arg	Arg	Ser	Pro	Gly	Val	Gly	Cys
274			515					520					525			
276	Val	Pro	Ala	Ala	Glu	His	Arg	Leu	Arg	Glu	Glu	Ile	Leu	Ala	Lys	Phe
277		530					535					540				
279	Leu	His	Trp	Leu	Met	Ser	Val	Tyr	Val	Val	Glu	Leu	Leu	Arg	Ser	Phe

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/424,686

DATE: 02/14/2002

TIME: 15:18:45

Input Set : A:\pto.vsk.txt

Output Set: N:\CRF3\02142002\I424686.raw

280	545	550	555	560
282	Phe Tyr Val Thr Glu Thr Thr Phe Gln Lys Asn Arg Leu Phe Phe Tyr			
283		565	570	575
285	Arg Lys Ser Val Trp Ser Lys Leu Gln Ser Ile Gly Ile Arg Gln His			
286		580	585	590
288	Leu Lys Arg Val Gln Leu Arg Glu Leu Ser Glu Ala Glu Val Arg Gln			
289		595	600	605
291	His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile			
292		610	615	620
294	Pro Lys Pro Asp Gly Leu Arg Pro Ile Val Asn Met Asp Tyr Val Val			
295		625	630	635
297	Gly Ala Arg Thr Phe Arg Arg Glu Lys Arg Ala Glu Arg Leu Thr Ser			
298		645	650	655
300	Arg Val Lys Ala Leu Phe Ser Val Leu Asn Tyr Glu Arg Ala Arg Arg			
301		660	665	670
303	Pro Gly Leu Leu Gly Ala Ser Val Leu Gly Leu Asp Asp Ile His Arg			
304		675	680	685
306	Ala Trp Arg Thr Phe Val Leu Arg Val Arg Ala Gln Asp Pro Pro Pro			
307		690	695	700
309	Glu Leu Tyr Phe Val Lys Val Asp Val Thr Gly Ala Tyr Asp Thr Ile			
310		705	710	715
312	Pro Gln Asp Arg Leu Thr Glu Val Ile Ala Ser Ile Ile Lys Pro Gln			
313		725	730	735
315	Asn Thr Tyr Cys Val Arg Arg Tyr Ala Val Val Gln Lys Ala Ala His			
316		740	745	750
318	Gly His Val Arg Lys Ala Phe Lys Ser His Val Ser Thr Leu Thr Asp			
319		755	760	765
321	Leu Gln Pro Tyr Met Arg Gln Phe Val Ala His Leu Gln Glu Thr Ser			
322		770	775	780
324	Pro Leu Arg Asp Ala Val Val Ile Glu Gln Ser Ser Ser Leu Asn Glu			
325		785	790	795
327	Ala Ser Ser Gly Leu Phe Asp Val Phe Leu Arg Phe Met Cys His His			
328		805	810	815
330	Ala Val Arg Ile Arg Gly Lys Ser Tyr Val Gln Cys Gln Gly Ile Pro			
331		820	825	830
333	Gln Gly Ser Ile Leu Ser Thr Leu Leu Cys Ser Leu Cys Tyr Gly Asp			
334		835	840	845
336	Met Glu Asn Lys Leu Phe Ala Gly Ile Arg Arg Asp Gly Leu Leu Leu			
337		850	855	860
339	Arg Leu Val Asp Asp Phe Leu Leu Val Thr Pro His Leu Thr His Ala			
340		865	870	875
342	Lys Thr Phe Leu Arg Thr Leu Val Arg Gly Val Pro Glu Tyr Gly Cys			
343		885	890	895
345	Val Val Asn Leu Arg Lys Thr Val Val Asn Phe Pro Val Glu Asp Glu			
346		900	905	910
348	Ala Leu Gly Gly Thr Ala Phe Val Gln Met Pro Ala His Gly Leu Phe			
349		915	920	925
351	Pro Trp Cys Gly Leu Leu Leu Asp Thr Arg Thr Leu Glu Val Gln Ser			
352		930	935	940

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/424,686

DATE: 02/14/2002

TIME: 15:18:45

Input Set : A:\pto.vsk.txt

Output Set: N:\CRF3\02142002\I424686.raw

```

354   Asp Tyr Ser Ser Tyr Ala Arg Thr Ser Ile Arg Ala Ser Leu Thr Phe
355   945                               950                               955                               960
357   Asn Arg Gly Phe Lys Ala Gly Arg Asn Met Arg Arg Lys Leu Phe Gly
358                               965                               970                               975
360   Val Leu Arg Leu Lys Cys His Ser Leu Phe Leu Asp Leu Gln Val Asn
361                               980                               985                               990
363   Ser Leu Gln Thr Val Cys Thr Asn Ile Tyr Lys Ile Leu Leu Leu Gln
364                               995                               1000                               1005
366   Ala Tyr Arg Phe His Ala Cys Val Leu Gln Leu Pro Phe His Gln Gln
367   1010                               1015                               1020
369   Val Trp Lys Asn Pro Thr Phe Phe Leu Arg Val Ile Ser Asp Thr Ala
370   1025                               1030                               1035                               1040
372   Ser Leu Cys Tyr Ser Ile Leu Lys Ala Lys Asn Ala Gly Met Ser Leu
373                               1045                               1050                               1055
375   Gly Ala Lys Gly Ala Ala Gly Pro Leu Pro Ser Glu Ala Val Gln Trp
376                               1060                               1065                               1070
378   Leu Cys His Gln Ala Phe Leu Leu Lys Leu Thr Arg His Arg Val Thr
379                               1075                               1080                               1085
381   Tyr Val Pro Leu Leu Gly Ser Leu Arg Thr Ala Gln Thr Gln Leu Ser
382   1090                               1095                               1100
384   Arg Lys Leu Pro Gly Thr Thr Leu Thr Ala Leu Glu Ala Ala Ala Asn
385   1105                               1110                               1115                               1120
387   Pro Ala Leu Pro Ser Asp Phe Lys Thr Ile Leu Asp
388                               1125                               1130

```


VERIFICATION SUMMARY

PATENT APPLICATION: US/09/424,686

DATE: 02/14/2002

TIME: 15:18:46

Input Set : A:\pto.vsk.txt

Output Set: N:\CRF3\02142002\I424686.raw

L:173 M:310 E: (3) Wrong or Missing Sequence Type, TYPE:



Attachment for PTO-948 (Rev. 03/01, or earlier)
6/18/01

The below text replaces the pre-printed text under the heading, "Information on How to Effect Drawing Changes," on the back of the PTO-948 (Rev. 03/01, or earlier) form.

INFORMATION ON HOW TO EFFECT DRAWING CHANGES

1. Correction of Informalities -- 37 CFR 1.85

New corrected drawings must be filed with the changes incorporated therein. Identifying indicia, if provided, should include the title of the invention, inventor's name, and application number, or docket number (if any) if an application number has not been assigned to the application. If this information is provided, it must be placed on the front of each sheet and centered within the top margin. If corrected drawings are required in a Notice of Allowability (PTOL-37), the new drawings **MUST** be filed within the **THREE MONTH** shortened statutory period set for reply in the Notice of Allowability. Extensions of time may **NOT** be obtained under the provisions of 37 CFR 1.136(a) or (b) for filing the corrected drawings after the mailing of a Notice of Allowability. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftsperson.

2. Corrections other than Informalities Noted by Draftsperson on form PTO-948.

All changes to the drawings, other than informalities noted by the Draftsperson, **MUST** be made in the same manner as above except that, normally, a highlighted (preferably red ink) sketch of the changes to be incorporated into the new drawings **MUST** be approved by the examiner before the application will be allowed. No changes will be permitted to be made, other than correction of informalities, unless the examiner has approved the proposed changes.

Timing of Corrections

Applicant is required to submit the drawing corrections within the time period set in the attached Office communication. See 37 CFR 1.85(a).

Failure to take corrective action within the set period will result in **ABANDONMENT** of the application.